Compare · COSM vs MCK
COSM vs MCK
Side-by-side comparison of Cosmos Health Inc. (COSM) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $116.43B, about 3439.3x COSM ($33.9M).
- COSM has been more active in the news (7 items in the past 4 weeks vs 4 for MCK).
- MCK has more recent analyst coverage (25 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- McKesson Corporation
- Price
- -
- -
- Market cap
- $33.9M
- $116.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 4
- Recent ratings
- 0
- 25
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest COSM
- Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
- Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
- SEC Form 8-K filed by Cosmos Health Inc.
- Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
- Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
- Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
- Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
- Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
- Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
- Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
Latest MCK
- SEC Form 8-K filed by McKesson Corporation
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
- McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
- McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $98,951 worth of shares (111 units at $891.45) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 521 units (SEC Form 4)
- McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
- RBC Capital Mkts initiated coverage on McKesson with a new price target
- SEC Form 4 filed by EVP and Chief Strategy Officer Srinivasan Ramesh (Nmn)
- Director Lerman Bradley E sold $268,590 worth of shares (301 units at $892.33), closing all direct ownership in the company (SEC Form 4)